Light activated chemotherapy for treatment of early-stage mouth cancers.

Developing new therapeutic solutions to improve patient function and long-term outcomes.
LEARN MORE
OVERVIEW

LightOx is headquartered in Newcastle upon Tyne, UK and is developing new light activated drug compounds. We are targeting a treatment for early stage and pre-cancerous lesions and are currently completing pre-clinical testing.

Our lead candidate will enter Phase I/2a study for the treatment of early-stage oral cancer lesions in 2022 with our clinical team in Liverpool, UK. With an IP portfolio consisting of five global patents, and a vibrant team experienced novel therapeutics, LightOx has a solid scientific and commercial base and looks to develop a range of treatments from its platform technology.

We are exploring projects and applications that spread beyond oncology targets, with the technology demonstrated in bacterial, fungal and plant species.

Our new technologies fundamentally change the way in which light-based therapies are delivered to the patient.

LightOx are developing a treatment that could be used in the dentist chair, by applying a gel to the affected area and activating the drug with light. Our modality is quick, simple and involves fewer side effects than surgery.
LEARN MORE
NEWS & EVENTS

Latest News

News & Events
OUR SOLUTION

LXD191

LightOx are developing a new class of light activated chemotherapy for the treatment of oral cancer. We use photosensitising agents along with light to kill cancer cells.
LEARN MORE
LIGHTOX

Probes

A Unique Range of Molecular Tools for use in Imaging, Therapeutics and Assay Development.
LEARN MORE